M3 : Notice Concerning Differences Between the Actual Consolidated Results for the Fiscal Year Ended March 31, 2023 versus the Respective Previous Fiscal Year
April 28, 2023 at 02:17 am EDT
Share
FOR IMMEDIATE RELEASE: 2023/4/28
Listed Name:
M3, Inc.
(TSE Prime Market; Ticker Code: 2413)
Headquarters：
(https://corporate.m3.com/en)
1-11-44 Akasaka, Minato-ku, Tokyo
Representative:
Itaru Tanimura, Representative Director
Contact:
Eiji Tsuchiya, Director
Phone'
03-6229-8900 (main line)
Notice Concerning Differences Between the Actual Consolidated Results
for the Fiscal Year Ended March 31, 2023 versus the Respective Previous Fiscal Year
This notice serves to provide information regarding the difference between actual consolidated results for the fiscal year ended March 31, 2023 and the respective results for the fiscal year ended March 31, 2022.
1. Differences between actual consolidated results for the fiscal year ended March 31, 2023 and the fiscal year ended March 31, 2022 (IFRS)
Profit Attributable
Net Sales
Operating Profit
Pre-Tax Profit
Net Profit
to Owners of the
Parent
Actual results for fiscal
Million Yen
Million Yen
Million Yen
Million Yen
Million Yen
year ended March 31,
208,159
95,141
96,187
66,108
63,845
2022 (A)
Actual results for fiscal
year ended March 31,
230,818
71,983
74,318
51,983
49,028
2023 (B)
Difference (B - A)
+22,659
-23,158
-21,868
-14,126
-14,817
Difference (%)
+10.9%
-24.3%
-22.7%
-21.4%
-23.2%
2. Reason of differences
The consolidated actual results of the net sales for the fiscal year ended March 31, 2023 notably exceeded the results from the previous year by more than 10%, due to factors such as the growth in sales and profits of the Evidence Solution business driven by the expansion of the domestic clinical trial projects for COVID- 19 and solid performance in each region of the Overseas segment. The operating profit, pre-tax profit and net profit for the current fiscal year were lower than those for the previous year. The decline can be attributed to the non-recurrence profit of 31.3 billion yen, which was recorded in the previous year due to the IPO on the Hong Kong Stock Exchange and equity-method affiliation of Medlive Technology Co., Ltd., a company with subsidiaries operating businesses in China.
Attachments
Original Link
Original Document
Permalink
Disclaimer
M3 Inc. published this content on 28 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2023 06:16:05 UTC.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3 : Notice Concerning Differences Between the Actual Consolidated Results for the Fiscal Year Ended March 31, 2023 versus the Respective Previous Fiscal Year
M3, INC. 
